The FDA said that other sections of the label, such as warnings and precautions ... CAR T cell therapies such as Gilead's (NASDAQ:GILD) Yescarta and Tecartus, Bristol Myers' (BMY) Breyanzi ...

The Food and Drug Administration ... Sciences' Kite Pharma (Yescarta), Johnson & Johnson (Carvykti), and Novartis (Kymriah) - directing them to submit proposed label changes within 30 days.

Priced at $373,000 per patient, Gilead’s Yescarta (axicabtagene ciloleucel) has just been approved by the FDA for adults with relapsed or refractory large B-cell lymphoma after two or more lines ...

ZUMA-7 is a randomized, open-label, global, multicenter, Phase 3 study evaluating the safety and efficacy of Yescarta versus standard of care (SOC) for second-line therapy in adult patients with ...

Largest Real-World Evidence (RWE) Analysis of Yescarta in Second-Line Shows 71% Overall Survival Rate, Consistent with Pivotal ZUMA-7 Study, in Broader Patient Population with Relapsed/Refractory ...